• Using the infectious SARS-CoV-2 (severe acute respiratory syndrome coronavirus-2), we are evaluating and developing new therapeutic drug candidates as well as evaluating disinfectants. Further analyses such as mechanism of action and resistance may be applicable. Other pathogens, including influenza virus and drug-resistant bacteria, will be examined upon request and discussion. Through joint and collaborative research with domestic and overseas pharmaceutical companies and related companies, we have experience of their clinical application including basic research.

We support development and evaluation of various inhibitors and disinfectants for variants of SARS-CoV-2 as well as wild type.

• SARS-CoV-2
• treatment
• disinfectants
• evaluation
• inhibitors
• virus
• Protein Structure Analysis